预约演示
更新于：2025-01-25
Penehyclidine hydrochloride
盐酸戊乙奎醚
更新于：2025-01-25
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H30ClNO2 |
InChIKeyDDTVVMRZNVIVQM-UHFFFAOYSA-N |
CAS号151937-76-7 |
关联
37
项与 盐酸戊乙奎醚 相关的临床试验NCT06624696
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia: a Double-blind, Randomized, Placebo-controlled Trial
ChiCTR2400089370
Penehyclidine for prevention of postoperative nausea and vomiting following temporomandibular joint surgery
ChiCTR2400085053
Effect of penehyclidine hydrochloride on postoperative nausea and vomiting in preoperative anxiety patients undergoing gynecologic outpatient surgery
100 项与 盐酸戊乙奎醚 相关的临床结果
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的转化医学
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的专利（医药）
登录后查看更多信息
1,650
项与 盐酸戊乙奎醚 相关的文献（医药）2025-02-01JOURNAL OF PHARMACOLOGICAL SCIENCES
Penehyclidine hydrochloride activates PARK2 and modulates ubiquitination of AIFM1 to rescue renal tubular injury in diabetic kidney disease
Article
作者: Tang, Jing ; Tan, HongBao ; Chen, Li
BACKGROUND:
Renal tubular injury (RTI) is one of the key characteristics of diabetic nephropathy (DN). Penehyclidine hydrochloride (PHC) was an anticholinergic drug with renoprotective effects, but its specific mechanism in the treatment of DN was still unclear.
METHODS:
We treated different diabetic mouse models and high glucose-induced RTI models by PHC. Histological analyses were performed using flow cytometry and staining, and ELISA evaluated the ROS, apoptosis, and related markers under different treatments. The molecular interactions were analyzed by ChIP, dual-luciferase reporter, and CoIP.
RESULTS:
PHC alleviated RTI by activating mitophagy and inhibiting apoptosis, and the protective effect could be rescued by PARK2 knockdown. Nrf2 bound to the promoter region of PARK2 and promoted its expression. PHC reduced the level of apoptosis by reducing the degree of nuclear translocation of AIFM1, which was rescued by PARK2 knockdown. PARK2 knockdown reduced the non-degradative ubiquitination of AIFM1, thus promoting its nuclear translocation and ultimately facilitating renal tubular cells (RTCs) apoptosis. The over-expression of AIFM1 rescued the RTCs apoptosis antagonized by PHC.
CONCLUSIONS:
PHC activated Nrf2 to up-regulate PARK2 transcription to induce mitophagy and inhibit apoptosis mediated by nuclear translocation of AIFM1 through promoting non-degradative ubiquitination of AIFM1, ultimately rescuing RTI in DN.
2025-01-15The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians4区 · 医学
Study on the application value of red blood cell distribution width and platelet distribution width in neonatal exchange transfusion with hyperbilirubinemia
4区 · 医学
Article
作者: Huang, Huifang ; Wu, Zhihui ; Chen, Qingting ; Zhong, Wenhui ; Chen, Lufei ; Wu, Kunhai
PURPOSE:
The study aimed to evaluate the application of Red Blood Cell Distribution Width (RDW) and Platelet Distribution Width (PDW) in the treatment of neonatal exchange transfusion (ET) with hyperbilirubinemia as well as to provide relevant reference materials for clinical diagnosis and treatment.
PATIENTS AND METHODS:
This was a retrospective study in a single center. Between January 2011 and December 2020, a total of 198 neonates, who were admitted to Fujian Maternity and Child Health Hospital for hyperbilirubinemia and treated with ET therapy were selected. They were divided into blood group antibody negative (BGAbN) ET (n = 92) and blood group antibody positive (BGAbP) ET (n = 106) groups. We analyzed changes in serum total bilirubin (STB), serum indirect bilirubin (SIB), and platelet count(PLT) before and after ET; The clinical data of the neonates with hyperbilirubinemia were collected, and RDW and PDW were compared in the two groups before ET..
RESULTS:
The concentrations of STB, SIB, and platelet count were much higher before ET and decreased significantly after ET; the difference was statistically significant (p<.001); There were significant differences between the two groups in RDW and PDW before ET.
CONCLUSION:
ET therapy is the most timely and effective treatment method for severe hyperbilirubinemia in neonates clinically; RDW and PDW can help determine neonatal hemolysis caused by blood group antibodies.
2025-01-01Journal of PeriAnesthesia Nursing
Penehyclidine Hydrochloride: A Promising Antimuscarinic Agent for PONV Prophylaxis in Diverse Surgical Procedures
Review
作者: Saber, Taisir ; AlHussaini, Khalid I ; Alkheder, Ahmad ; Abo Zeid, Mohamed ; Elrosasy, Amr ; Aissa, Sara Chikh ; Hawas, Yousef ; El-Nablaway, Mohammad ; Sarhan, Khalid ; Khodeer, Dina M ; Abu Salah, Mariam A
PURPOSE:
The purpose of this meta-analysis is to measure the effectiveness of penehyclidine hydrochloride hydrate (PHC)-an antimuscarinic drug-in preventing postoperative nausea and vomiting (PONV) for different surgeries.
DESIGN:
Meta-analysis.
METHODS:
According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, we conducted an online literature search using PubMed, Web of Science, Scopus, and Embase databases. Randomized control trials comparing PHC with placebo or any other standard treatments were included.
FINDINGS:
Our systematic review screened 54 articles, and four randomized control trials with 766 patients were included. There was no significant difference between PHC and the control group for the prevention of postoperative vomiting (risk ratio [RR] = 0.43). However, the subgroup analysis showed some promise. At 24 hours, PHC significantly decreased the incidence of postoperative nausea (RR = 0.31), postoperative vomiting (RR = 0.17), and PONV (RR = 0.33). While at 48 hours, PHC showed nonsignificant results for the same outcomes. PHC did not result in significantly higher rates of analgesia use, headache, dizziness, longer durations of stay in the postanesthesia care unit, or longer duration for extubation, but it showed significantly lower results for the use of antiemetics. Furthermore, PHC showed higher rates of dry mouth.
CONCLUSIONS:
The findings suggest that PHC offers a promising option for PONV prophylaxis, particularly in surgical settings where early PONV are prevalent, with an acceptable safety profile. Further research is recommended to optimize dosing strategies and compare PHC with established antiemetics.
100 项与 盐酸戊乙奎醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2002-10-24 | |
| 药物中毒 | 中国 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆道痛 | 临床2期 | 中国 | 2017-05-19 | |
| 胆道痉挛 | 临床2期 | 中国 | 2017-05-19 | |
| 慢性阻塞性肺疾病 | 临床2期 | 中国 | 2008-07-21 | |
| 脓毒性休克 | 临床1期 | 中国 | 2012-06-11 | |
| 帕金森病 | 临床1期 | 中国 | 2012-03-15 | |
| 休克 | 临床1期 | 中国 | 2012-03-15 | |
| 平滑肌痉挛 | 临床1期 | 中国 | 2012-03-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | 願衊構鑰淵艱壓顧醖鹽(鹽鏇獵鹽獵蓋範製範醖) = 壓繭鹽醖淵構遞積醖願 齋獵繭餘膚窪蓋鏇憲壓 (遞願顧選選簾鏇製網鏇 ) | - | 2022-10-14 | ||
TIVA group | 願衊構鑰淵艱壓顧醖鹽(鹽鏇獵鹽獵蓋範製範醖) = 製構構鬱願網獵蓋繭淵 齋獵繭餘膚窪蓋鏇憲壓 (遞願顧選選簾鏇製網鏇 ) | ||||||
临床3期 | - | 864 | 範鏇窪網觸製糧選繭夢(艱積鏇廠範繭鬱憲壓糧) = dry mouth and delirium 膚淵繭獵範鹽積選鹹憲 (獵鏇築齋淵餘觸鬱衊膚 ) | 积极 | 2022-04-01 | ||
Placebo | |||||||
临床4期 | 228 | 糧鑰襯願觸獵網願遞鹹(製願積簾齋範淵網製獵) = 鏇願構獵鹽獵製鹹襯網 夢製夢淵夢鹹觸繭鹽積 (鹽糧夢膚遞顧醖襯獵製 ) 更多 | - | 2021-02-13 | |||
糧鑰襯願觸獵網願遞鹹(製願積簾齋範淵網製獵) = 願齋壓鹽鬱鹹鏇鬱糧艱 夢製夢淵夢鹹觸繭鹽積 (鹽糧夢膚遞顧醖襯獵製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用